News for scPharmaceuticals Inc. (SCPH)

Operator: Good afternoon and welcome to scPharmaceuticals First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode.

Net Revenue: $11.8 million for Q1 2025.FUROSCIX Doses Filled: Approximately 13,800 doses in Q1 2025.Gross to Net Discount: Approximately 23% in Q1 2025, with a

May 14, 2025 / 08:30PM GMTOperator Good afternoon and welcome to scPharmaceuticals first-quarter 2025 earnings conference call. (Operator Instructions) As a rem

scPharmaceuticals reports strong Q1 2025 results, driven by FUROSCIX's CKD launch, rising Medicare patient fill rates, and projected growth with COGS...

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ETCompany ParticipantsWilliam Thorpe - Investor RelationsJohn...

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -25.93% and 3.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

**media[618053]**

BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. ( SCPH) (the ”œCompany”), a pharmaceutical company committed to revolutionizing

scPharmaceuticals Inc (SCPH) is set to release its Q4 2024 earnings on Mar 19, 2025. The consensus estimate for Q4 2024 revenue is $12.83 million, and the earni

Fourth Quarter Revenue: $12.2 million, up from $6.1 million in Q4 2023.Full Year Revenue: $36.3 million, a 167% increase from $13.6 million in 2023.Cost of Pro

**media[533440]**

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid

Overview of the Recent Transaction On November 14, 2024, King Luther Capital Management Corp made a significant addition to its investment portfolio by acquirin

scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsNick Colangelo - Investor...

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -23.33% and 7.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[465437]**

Overview of the Recent Transaction KING LUTHER CAPITAL MANAGEMENT CORP (Trades, Portfolio), a prominent investment management firm, recently increased its holdi

TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024